San Diego, California–(Newsfile Corp. – April 5, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“ Tryp” or the “Company“) a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today it has initiated quoting activity on the OTCQB® Venture Market (the “OTCQB“) and is eligible for settlement and transfer of its common shares in…


Previous articlePT238 – Kile Ortigo – Integration and Existential Exploration
Next articleMydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical